The PI work is concerned with the study of manipulation of corneal cell growth and the diminution of T cell dependent inflammatory responses in corneal injury and a model of uveitis. He has developed a new class of structurally designed immunologic mimetics for these studies. the compounds were designed from discrete complementarily determining regions of a particular anti-receptor antibody and another member of the immunoglobulin gene family, CD4. These molecules operate via novel mechanisms and offer the opportunity to study agonist and antagonistic effects on receptor specific functions. The small CDR form designed from the anti-receptor antibody stimulates corneal cell growth and accelerates corneal would defect closure. This CDR form has an opposite affect on activated T cells in which it inhibits activation. This compound will be studied in corneal damage associated with herpes simplex disease and in other studies dealing with corneal defects. The compound developed from CD4 has the ability to inhibit T cell activation. This compound will be studied in models of T cell dependent corneal inflammation and in models of uveitis. These compounds have many chemical and immunologic benefits over the intact macromolecules from which they were derived.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
3R01EY009332-14S1
Application #
6459995
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Fisher, Richard S
Project Start
1986-05-01
Project End
2001-10-31
Budget Start
2000-07-01
Budget End
2001-10-31
Support Year
14
Fiscal Year
2001
Total Cost
$36,333
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104